Sunteți pe pagina 1din 10

Click to edit Master title style

4/20/2013

Clinical Development

Novel Target Validation

How we Help 1. Lower Cost


(less Man-hours)
Pre Clinical Development Lead Optimization

2. Reduce Failure Rate

1. 2. 3.

$ 1 Billion to get a drug to market 15 years to develop and get approved 20 year Patent Life = 5 years of protected sales

3. Time Saver
(Extends Patent life)

4. Increase Probability of Success


4/20/2013 2

Stage 1. Novel Target Validation Lead Optimization Pre-Clinical Development Clinical Development

Outcomes
Develop Compound Identify Indication Safety/Tolerability Feasibility

Stats
2 -4 years 75% Failure Rate 10% of cost 1-3 years 80% Failure Rate 15% of cost 1-2 years 67% Failure Rate 25% of cost 6- 8 years 80% Failure Rate 50 % of cost

After Blue Atom


1-3 Months 60 % Failure Rate 5 % of cost
6-9 Months 65 % Failure Rate 7.5 % of cost 5 -12 Months 52 % Failure Rate 12.5% of cost 6- 8 years 80% Failure Rate 75 % of cost (Potential) 10 years $750 Million Success = 1500/10,000

Product Interactions
nFlow Chemically Aware

2.

nFlow Chemically Aware

3.

Animal Testing Formulation Clinical Trials IND Filing Compound Repositioning

nFlow

4.

FDA Approval
5. Sales $$$ Billion Dollar Market

nFlow Chemically Aware Compound Repositioning

15 years $1 Billion Success = 1/10,000

4/20/2013

Differentiation Chemical Structure Search (Optical Structure Recognition) Compound Repositioning

Result Compound Likeness/Competitive Therapeutic Indication based on best probability

Stage Interaction Stage 1

Year 3 revenues = $1,614,375 (net discounts) Customer Count = 32 new | 40 renewals

Stage 2 4

Technology: Database Driven Application that sits on MS SharePoint (Industry leading collaboration tool)

Differentiation Business Process Workflow Automation Competitive Intelligence

Result Automates Safety/Tolerability/Feasibility modeling and lab data readout Uses Publicly Available data including FDA and Publication sites Identifies Most Viable compounds for targeted indications

Stage Interaction Stage 2 & 3

Stage 2

Year 3 revenues = $7,382,500 Customer Count = 10 new | 13 renewals

Consensus Scoring

Stage 2

Technology: Data Warehouse Driven Dashboard

4/20/2013

Key Points: Compound Screening and Repositioning, Third party integration, Patented Algorithm
Product Chem4SharePoint Search Genius SharePoint WebPart Company Scigillence Perkin Elmer Accelrys SubStructure Search Yes Yes No Compound Reposition No No No Compound Screening No No No Deficiencies Inefficient, No integration with other products High Priced tag Static searches, inconclusive results

Key Points: Consensus Scoring, fully integrated to environment


Product In-House Application HEOS Company Large pharma Assay Workflow No Consensus Scoring No Third Party/Lab Integration Specific to products owned by company No Deficiencies High development costs, development dependent on Success Service based, Web only

Accelrys

Yes

No

4/20/2013

15 % Big Pharma (GSK, Merck, Pfizer, J&J)

Roche Genentech Eisai Cleveland Clinic

nFlow Chemically Aware

Demo Complete or potential lead In discussions

9% Medium Pharma ( Targacept, Allergan, Etc.)


76% Small Pharma (Start-ups, emerging)

H3Biomed AMB

nFlow Chemically Aware

ASINEX

nFlow Chemically Aware

In discussions

% 20

Type Direct Sales

Components Sales Training Implementation (services)

80

Channel Partner (Perkin Elmer, Pharmica, Dell)

4/20/2013

POC in non-NNR/CNS pharmaceutical company Acceptance of Grant submissions by NIH and HHS for continued development of product capabilities

Collaboration Partnerships with complementary product integrate additional functionality


Funding by investor to retain and hire key personnel

4/20/2013

Developers with Mobility and Cloud experience


Collaboration partners to validate results and peer review product capabilities Wide adoption of the technologies which will enable faster results and streamline the products

4/20/2013

Industry is researching the problem for resolution Large academia pool of computational chemists and biological modelers to pull from Federal Government funding opportunities of this nature to solve the cost, time and success of drug discovery Application goes beyond drugs to auto, biofuel and bioenergy industries

4/20/2013

Name

Position

Experience

Miles Romello CISSP, CISRC

CEO/CTO

20 Yrs. IT (Hands on & leadership) Wachovia (Corporate Information Security Manager) Targacept (Sr. Director Information Technology) Former CEO for Startup Internet Caf (90s)
15 years in IT leadership and operations Targacept Womble Carlyle Litera Corp. Masters in Information Systems Innovator of Blue Atom Technology 10 years Development Experience Published 23 years Life Sciences Published Tied to numerous patents

Chandra Holcomb

VP Operations

Kartik Tallapragada Phd Candidate Dr. David Kombo, Phd

Software Development

Computationa l Chemistry

Mauri Hodges CPA, CCP

Board Chairman

Executive in Targacept for 15 years Former CEO for software development company Experience with start-up companies, venture funding, IPO and acquisitions 4/20/2013

10

S-ar putea să vă placă și